Containment Contamination Contract Manufacturing 
Pharmaceutical Technology
NOVEMBER 17, 2022
According to GlobalData analysis, specialist small molecule API capabilities such as containment or controlled substances are driving large contract manufacturing organisations (CMOs) to acquire facilities. Flexible containment solutions for potent APIs. Partnering with containment experts.
Pharmaceutical Technology
DECEMBER 6, 2022
Manufacturing these highly potent and often cytotoxic drugs introduces many risks for operators and the environment. Cross-contamination of standard products with highly potent ones is another key concern. Many companies are now prioritising investments in containment systems, GlobalData research shows.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
JUNE 14, 2023
This, coupled with small pharma companies being unable to acquire or access containment capabilities in-house, means that the demand for innovative specialized small molecule capabilities remains high. Premium specialized equipment is necessary because high containment facilities call for the separation of the operator from the product.
Pharmaceutical Technology
SEPTEMBER 15, 2022
Research by GlobalData (Contract Small Molecule API Manufacturing Industry by the Numbers – 2021 Edition) shows that containment facilities are in high demand as the use of cytotoxic drugs continues to grow. This suggests a move towards high-value specialised manufacturing. Containment challenges.
Pharmaceutical Technology
APRIL 12, 2023
The ingredients used in these drugs are high potency, even at small doses, and pose a risk to both human health and cross-contamination with other drugs in a manufacturing environment. Currently mostly outsourced, there are signs that CMOs are beginning to make investments in containment capabilities, to capture emerging opportunities.
Roots Analysis
APRIL 15, 2024
Additionally, the fill finish manufacturing of biologics is a critical step in the production of biopharmaceuticals as it requires well-equipped facilities with adequate sterile filling and packaging lines to ensure sterility of the product while filling into the final containers.
Roots Analysis
OCTOBER 24, 2023
Considerations of Handling High Potency Active Pharmaceutical Ingredients HPAPIs have difficult handling requirements which require various measures to be taken into consideration such as primary containment measures and secondary containment solutions. Secondary containment strategy include personnel training and awareness programs.
Expert insights. Personalized for you.
130 
Let's personalize your content